A bio-based fungicide leveraging a native Pseudomonas protegens strain (PS11) that inhibits Sclerotinia sclerotiorum and Botrytis cinerea by 90-100% in vitro while promoting plant growth. Designed for greenhouse and field tomato cultivation, with planned biochar and nano-emulsion formulations to improve soil health, yield, and disease resistance.
This solution introduces a novel microbial fungicide based on a native bacterial strain, Pseudomonas protegens (PS11), isolated and characterized through 16S sequencing. The strain demonstrated 90-100% inhibitory activity against two major tomato pathogens, Sclerotinia sclerotiorum and Botrytis cinerea, in laboratory antagonistic assays. Beyond disease suppression, PS11 exhibits multiple plant growth-promoting traits, offering a dual benefit of pathogen control and improved crop performance. The technology targets greenhouse and open-field tomato production, where fungal diseases cause significant yield losses, and aims to reduce reliance on chemical fungicides.
Key features:
Validation status:
The technology is currently at an early-to-mid stage of development. The core biological mechanism has been validated in vitro, confirming both antifungal efficacy and plant growth-promoting capabilities of the PS11 strain. Future validation will focus on greenhouse trials using two formulation approaches (biochar and nano-emulsion in lemongrass essential oil) to evaluate disease severity reduction in tomato cultivars, followed by field studies. Additional investigations will assess the impact of PS11 application on soil microbial diversity, plant immunity gene expression, and volatile compound production. Further development, including formulation optimization, scale-up fermentation, regulatory assessment, and multi-location field trials, is needed before commercial deployment.
University of Malaya is Malaysia’s oldest comprehensive public research university with broad disciplinary depth and a strong national role. Its Kuala Lumpur campus places corporate partners minutes from regional headquarters and supply‑chain nodes, while specialized labs and shared core facilities support contract R&D, testing, and validation. Integration with an on‑campus teaching hospital enables clinical studies and translational work, and industry liaison and professional education groups streamline access to talent and upskilling. Research is supported by competitive funding from Malaysian government agencies and international sponsors, complemented by direct industry collaborations. A dedicated technology transfer office manages IP, licensing, and startup formation with clear pathways for rapid engagement.